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Sequence and biochemical characterization of equilibrative nucleoside
transporters from Crithidia fasciculata: seeking ligand binding residues
Abstract
Eukaryotic cells acquire purines via de novo synthesis or salvage mechanisms. Unlike human cells, protozoan
parasites from the Apicomplexan and Trypanosomatid lineages such as Plasmodium, Toxoplasma, Leishmania,
Trypanosoma and Crithidia species lack de novo purine synthesis enzymes, and therefore rely on salvage of pre-
formed purine bases for growth and proliferation, making purine salvage an attractive drug target. A key step
in purine salvage is transport of purine nucleobases and nucleosides into the cell, and each species encodes a
unique repertoire of transporter proteins from the equilibrative nucleoside transporter (ENT) family, each
with its own ligand preference. No detailed structural information for ENT proteins yet exists, but residues
within four of the eleven transmembrane domains (TMs) appear to be important for ligand selectivity.
Recently we have described the pivotal role of a lysine residue within TM4 of the Crithidia fasciculata purine
nucleoside transporter Cf NT2 in ligand discrimination. Here we describe the cloning of additional ENT
genes from C. fasciculata using partial genomic sequencing and molecular techniques, and biochemical
characterization of the encoded proteins. The role of sequence variations among the C. fasiculata ENTs in
determining ligand preference may shed additional light on residues and regions of ENTs that contribute to
ligand binding.
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Program Number 699.1 INTRODUCTION
Eukaryotic cells acquire purines via de novo synthesis or salvage mechanisms. Unlike 
human cells, protozoan parasites from the Apicomplexan and Trypanosomatid lineages 
such as Plasmodium, Toxoplasma, Leishmania, Trypanosoma and Crithidia species 
lack de novo purine synthesis enzymes, and therefore rely on salvage of pre-formed 
purine bases for growth and proliferation, making purine salvage an attractive drug 
target in these organisms. A key step in purine salvage is transport of purine 
nucleobases and nucleosides into the cell, and each species encodes a unique 
repertoire of transporter proteins from the equilibrative nucleoside transporter (ENT) 
family, each with its own ligand preference. ENT proteins have 11 transmembrane 
domains (TMs; see the figure), and residues that affect ligand specificity in a number of 
different ENTs have been identified in TMs 1, 2, 4 and 5 (see [1]). 
We are interested in identifying additional residues that impact ligand affinity and specificity in these transporters in order to further define 
the ligand binding site. Previous work has shown that adenosine transport in Crithidia fasciculata (a close relative of the Leishmania spp.) 
is carried out by CfNT1 as well as at least one other adenosine transporter [2].  We therefore cloned genes encoding additional adenosine- 
transporting ENTs in C. fasciculata to determine if they would be suitable for construction of chimeras to identify additional regions of the 
transporter sequence that influence ligand specificity. Good candidates would be highly similar in protein sequence but biochemically 
distinguishable. Here we describe the cloning of CfNT1-like genes from C. fasciculata using genomic sequencing and molecular 
techniques, and preliminary biochemical characterization of one novel adenosine transporter, CfAT1. The role of sequence variations 
between CfAT1 and CfNT1 in determining ligand preference may shed additional light on residues and regions of ENTs that contribute to 
ligand binding. 
RESULTS
1 Genomic sequences of additional CfNT1-like genes were obtained by whole genome sequencing and molecular methods.
Genome sequence data were obtained by whole genome shotgun sequencing of Crithidia fasciulata clone Cf-C1 (obtained from Larry Simpson, UCLA), 
using Sanger or several generations of 454 sequencing technologies at the Washington University genome sequencing center. Blast searches of the 
individual reads generated were performed first with CfNT1, which yielded evidence of additional genes. 5’ RACE and further iterations of blast 
searching with these genes against preliminary genomic assemblies ultimately led to the identification of four genes in total, which were named CfAT1, 
CfAT1.2, CfNT3 and CfNT1.2. Only the 3’ 75% of the CfNT1.2 gene has been defined to date. Consistent with other genome sequence data suggesting 
a high level of heterozygosity in Crithidia fasciculata, some of these putative genes are allelic (see next panel). 
2 DNA sequence analysis indicates that 
CfAT1/CfAT1.2 and CfNT1/CfNT1.2 are alleles 
rather than distinct genes.
The low number of nonsynonymous DNA sequence 
changes and high level of identity in flanking regions 
support assignment of these sequences as alleles.
3 The novel proteins CfAT1 and CfNT3 are more similar in sequence 
to adenosine transporters than they are to inosine-guanosine or 
nucleobase transporters.
A multiprotein sequence alignment and phylogram were generated using Clustal 2.0.12 
(www.ebi.ac.uk). CfNT1 and LdNT1 are adenosine transporters from C. fasciculata and 
Leishmania donovani, respectively[2,3]. CfNT2 and LdNT2 are inosine-guanosine transporters 
from the same two organisms [2,4]. LmaNT3 and LmaNT4 are nucleobase transporters from L. 
major [5,6]. CfAT1 and CfNT3 clearly cluster with the other adenosine transporters, suggesting 
that they are also likely to be adenosine transporters.
5 CfAT1 has a 25-fold higher apparent affinity for adenosine 
than does CfNT1.
6 Unlike CfNT1, CfAT1 does not appear to have any other ligands among the 
naturally occurring purines and pyrimidines.
A protein sequence alignment wa s 
produced using Clustal 2.0.12. CfAT1 is ~ 
87% identical and 93% similar to CfNT1 at 
the protein level, suggesting that chimeras 
between these two proteins may be 
structurally sound. CfNT3 is significantly 
more divergent in sequence, with only 
~73% identity to CfNT1 and CfAT1 at the 
protein level. CfNT3 deviates most 
significantly from the other two 
transporters in TMs 6 through 8. The 
significance of this portion of the protein to 
transporter function is unknown.
Nonhomologous substitutions between 
CfNT1 and CfAT1 are concentrated in the 
N-terminal region and other loops (esp. 
the large intracellular 6-7 loop). The K to T 
variation in TM4 may be important for 
ligand specificity, as the homologous 
residue in two other transporters has this 
function (LdNT1 [7] and CfNT2 [1]) as 
well. Additional changes appear in TMs 7, 
8, 9 and 10. While TMs 7, 8 and 10 are 
thought to lie on ligand translocation 
channel of ENTs [8], it is not known if 
residues in these TMs contribute to ligand 
binding. 
CfAT1 CfNT1
CfAT1 was expressed in L. donovani lacking purine nucleoside uptake, and CfNT1 was expressed 
in Xenopus oocytes [2]. Uptake of 3H-adenosine into cells in the presence of a 100-fold excess of 
unlabeled inhibitor was measured over 5 sec and 45 min for CfAT1- (purple) and CfNT1- 
expressing (blue) cells, respectively. Uptake is expressed relative to uninhibited control cells. 
Tubercidin is a toxic adenosine analog.
CfAT1 and CfNT1 were expressed in L. donovani cells lacking endogenous purine 
nucleoside uptake. Uptake of 3H-adenosine into cells was measured by the oilstop method 
over a 15 sec and 30 sec timecourse for CfAT1- (purple) and CfNT1-expressing (blue) 
cells, respectively, at each concentration. Km values of ~1 and ~27 μM were calculated 
from fitting Michaelis-Menten curves in Graphpad Prism 5.01.
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• There are at least three distinct adenosine transporter genes in Crithidia fasiculata.
• CfNT1 and CfAT1 differ in protein sequence in several regions of interest, including TMs 2 & 4, which may influence ligand 
specificity, and the large loop intracellular loop between TMs 6 and 7 whose function is unknown.
• CfNT1 and CfAT1 have distinct biochemical properties, specifically in their apparent affinities for adenosine, and their abilities 
to be inhibited by inosine and hypoxanthine.
• Chimeras of these two transporters should produce functional proteins, and could allow the identification of functionally 
significant protein sequence differences and novel ligand specificity determinants.
• Biochemical characterization of the more divergent putative adenosine transporter CfNT3 is ongoing.
4 Protein sequence alignment of CfNT1, CfAT1 and CfNT3 shows that interesting sequence variations are confined to a few regions of the 
transporters. 
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